News FDA starts priority review of BeOne's Venclexta rival BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.
News Approvals extend use of Roche, AbbVie drugs in lymphoma Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.
News Filmmaker helps AbbVie spread the word about leukaemia AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.
News AbbVie exits alliance with Alphabet biotech Calico; report Reports are emerging that a multibillion-dollar partnership between AbbVie and Calico has come to an end after more than a decade.
News AbbVie joins BMS in taking a hard line on UK drug pricing AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.
News AbbVie loses bid to block 340B law in Mississippi Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.